Loading
A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly is a phase 3 interventional study registered as NCT01137682 by Novartis Pharmaceuticals, with 198 participants recorded, started 2010-07-19 and reaching its primary completion in 2013-01-22. Interventions recorded: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg. Conditions recorded: Acromegaly.
Linked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
198 enrolled.
95% CI 7.63 to 26.48; Figures from the ClinicalTrials.gov results section (first posted 2015-01-21), not from a publication · 95% CI 11.10 to 31.77 · 95% CI 0 to 5.28
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.primary | Pasireotide LAR 40 mg | 65 | 15.4% | - | - | link |
| Pasireotide LAR 60 mg | 65 | 20% | ||||
| Control Arm (Octreotide or Lanreotide) | 68 | 0% |
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pasireotide, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, Novartis and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.